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(WOBJECTIVES This study sought to compare the performance of major guidelines for the assessment of stable chest pain
including risk-based (American College of Cardiology/American Heart Association and European Society of Cardiology)
and symptom-focused (National Institute for Health and Care Excellence) strategies.
BACKGROUND Although noninvasive testing is not recommended in low-risk individuals with stable chest pain,
guidelines recommend differing approaches to deﬁning low-risk patients.
METHODS Patient-level data were obtained from the PROMISE (Prospective Multicenter Imaging Study for Evaluation
of Chest Pain) and SCOT-HEART (Scottish Computed Tomography of the Heart) trials. Pre-test probability was
determined and patients dichotomized into low-risk and intermediate-high–risk groups according to each guideline’s
deﬁnitions. The primary endpoint was obstructive coronary artery disease on coronary computed tomography
angiography. Secondary endpoints were coronary revascularization at 90 days and cardiovascular death or nonfatal
myocardial infarction up to 3 years.
RESULTS In total, 13,773 patients were included of whom 6,160 had coronary computed tomography angiography.
The proportions of patients identiﬁed as low risk by the American College of Cardiology/American Heart Association,
European Society of Cardiology, and National Institute for Health and Care Excellence guidelines, respectively,
were 2.5%, 2.5%, and 10.0% within PROMISE, and 14.0%, 19.8%, and 38.4% within SCOT-HEART. All guidelines
identiﬁed lower rates of obstructive coronary artery disease in low- versus intermediate-high–risk patients with a
negative predictive value of $0.90. Compared with low-risk groups, all intermediate-high–risk groups had greater
risks of coronary revascularization (odds ratio [OR]: 2.2 to 24.1) and clinical outcomes (OR: 1.84 to 5.8).
CONCLUSIONS Compared with risk-based guidelines, symptom-focused assessment identiﬁes a larger group of
low-risk chest pain patients potentially deriving limited beneﬁt from noninvasive testing. (Scottish Computed
Tomography of the Heart Trial [SCOT-HEART]; NCT01149590; Prospective Multicenter Imaging Study for Evaluation
of Chest Pain [PROMISE]; NCT01174550) (J Am Coll Cardiol Img 2018;11:1301–10) © 2018 The Authors. Published by
Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).N 1936-878X https://doi.org/10.1016/j.jcmg.2018.06.021
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1302T he safe and efﬁcient assessmentof individuals presenting with sus-pected stable angina is fraught
with challenge. At an individual level, clini-
cians and patients alike are highly motivated
to determine the cause of symptoms and
identify the presence of underlying coronary
artery disease (CAD) that may place the
patient at high risk of future cardiovascular
events. Given the resource-intensive nature
of cardiac investigations, this tendency
toward risk aversion must be balanced on
a population level by efﬁcient diagnostic
pathways that minimize unnecessary or
inappropriate testing.
Optimizing this balance of safety and
efﬁciency underpins the principles of inter-national clinical guidelines. In recent years, 3 distinct
approaches have been independently adopted by
the American College of Cardiology/American Heart
Association (ACC/AHA) (1,2), the European Society of
Cardiology (ESC) (3), and the U.K. National Institute
of Health and Care Excellence (NICE) (4,5).SEE PAGE 1311Both the ACC/AHA and ESC guidelines adopt
the concept of Bayesian probability whereby initial
estimation of prior probability is updated according
to diagnostic test results to determine the post-
test probability of obstructive CAD. Within these
risk-based strategies, pre-test probability (PTP) is
determined from the DF-CASS (Diamond-Forrester/
Coronary Artery Surgery Study) (ACC/AHA) (2) and
CADC (Coronary Artery Disease Consortium) (ESC) (3)
clinical risk scores that incorporate age, sex, and
chest pain typicality. Knowledge of PTP is used to
categorize patients into 1 of 3 diagnostic risk groups:
low; intermediate; or high. Both guidelines agree
that noninvasive testing for CAD has greatest utility
(Class I recommendation) in the intermediate-risk
group, which is arbitrarily deﬁned as 10% to 90%
in the United States and 15% to 85% in Europe.
In contrast, the recently updated NICE guidance for
the diagnosis of suspected stable angina has aban-
doned this probabilistic approach in favor of a
symptom-focused assessment (4). Following clinical
evaluation, patients adjudged to have typical or
atypical symptoms or an abnormal restingl research funds from GE Healthcare and HeartFlow; and serves o
serves on advisory boards for Bayer, Novo Nordisk, Boehringer In
ave no relationships relevant to the contents of this paper to dis
received June 26, 2018; accepted June 29, 2018.electrocardiogram are categorized into a possible
angina group for whom additional noninvasive im-
aging with coronary computed tomography angiog-
raphy (CCTA) is recommended. The remainder are
classiﬁed as nonanginal, and no further testing is
indicated.
However, the impact of these recommendations
on the appropriate selection of patients for the
application of these tests remains underexplored in
prospective clinical trials. Indeed, while all 3 of the
guidelines recognize the limited utility of diagnostic
testing in low-risk individuals, each has adopted
important differences in approach to deﬁning this
cohort. To our knowledge, no prior study has sys-
tematically compared the results of the 3 approaches
to identify obstructive CAD and clinical outcomes.
Thus, we studied the efﬁciency and safety of the
3 major guidelines for the diagnosis of obstructive
CAD in patients with stable chest pain within
the context of 2 recent large clinical studies—the
North American, PROMISE (Prospective Multicenter
Imaging Study for Evaluation of Chest Pain), and the
SCOT-HEART (Scottish Computed Tomography of
the Heart) trial.
METHODS
STUDY COHORTS. Patient-level data were obtained
from the PROMISE and SCOT-HEART trial cohorts.
These are prospective multicenter randomized
controlled trials investigating the utility of CCTA in
the diagnosis and management of patients undergo-
ing assessment of suspected stable angina due
to CAD. The pragmatic designs (6,7) and principal
ﬁndings (8,9) of these studies have been reported
previously. The intervention arm in both studies
consisted of CCTA, which was compared with usual
care. Details of cohort-speciﬁc inclusion and exclu-
sion criteria have been previously described (10). To
conﬁrm guideline utility in distinct clinical settings
and across populations, the study cohorts were
analyzed separately.
GUIDELINE-DETERMINED DIAGNOSTIC GROUPS.
For the ACC/AHA and ESC guideline analysis, PTP of
CAD was determined according to the DF-CASS
and CADC risk models, respectively. Diagnostic risk
groups (low, intermediate, high) were then deﬁned as
speciﬁed in each guideline (Online Table 1). Forn a data safety monitoring board for GE Healthcare.
gelheim, and Sanoﬁ. All other authors have reported
close.
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1303the purposes of this analysis, we have combined
the intermediate- and high-risk patients into a single
intermediate-high–risk diagnostic group who are
likely to require further diagnostic testing. For the
NICE guideline analysis, patients with nonanginal
symptoms and a normal resting electrocardiogram
were classiﬁed as low risk with the remainder
categorized as intermediate-high risk.
CORONARY IMAGING. Patients randomized to the
intervention arms of both trials underwent cardiac
imaging with contrast-enhanced CCTA using a
64-slice or greater multidetector CT scanner. The
presence of obstructive CAD was deﬁned as site
interpretation of $70% area stenosis in any major
epicardial vessel or $50% stenosis in the left main
stem. In concordance with the ACC/AHA guideline,
we additionally determined the presence of prog-
nostically signiﬁcant CAD, deﬁned as 3-vessel
disease, 2-vessel disease including the proximal left
anterior descending artery, or obstructive disease
involving the left main stem.
ENDPOINTS. The primary (diagnostic) endpoint
was the presence of obstructive CAD on coronary
imaging in those individuals randomized to the CCTA
intervention arm who underwent this test as part
of the initial trial protocols.
The secondary endpoints were determined from
the entire study cohort of both trials and included
coronary revascularization at 90 days—either coro-
nary artery bypass grafting or percutaneous coronary
intervention—and cardiovascular death or non-fatal
myocardial infarction up to 3 years. The time point
of 90 days reﬂects the duration of follow-up for this
endpoint within the PROMISE trial and was chosen
to capture CCTA-driven alterations in coronary
revascularization. Longer-term outcome data for fatal
and nonfatal cardiovascular events was recorded in
all patients up to 1 year in PROMISE and up to 3 years
in SCOT-HEART.
STATISTICAL ANALYSIS. Statistical analysis was per-
formed using R (version 3.4.3, R Foundation for
Statistical Computing, Vienna, Austria) and SAS
(version 9.4, SAS Institute, Inc., Cary, North Car-
olina). All analyses were post hoc and were stratiﬁed
by study cohort and according to intention-to-treat,
irrespective of compliance with scanning. The diag-
nostic and revascularization endpoints were
analyzed using chi-squared tests and log-binomial
regression (11,12), with results are reported as odds
ratios (ORs) with 95% conﬁdence intervals (CIs) and p
values. Clinical events were analyzed with Cox
regression and reported as hazard ratios (HRs) withcumulative incidence plots constructed. Additional
performance measures were determined including
discrimination, sensitivity, speciﬁcity, positive pre-
dictive value, and negative predictive value. In
PROMISE, these performance measures were
assessed 1 year post-randomization using the method
of Heagerty et al. (13) to account for those lost to
follow-up in the trial. In addition to these stratum-
speciﬁc analyses, we modeled interaction terms for
allocation and within study cohort to provide hy-
pothesis testing for interaction on the relative scale.
Comparison of diagnostic metrics including predic-
tive values between the overlapping groups of pa-
tients determined to be low risk by each of the 3
guidelines were made using previously described
methods (14–17). Net reclassiﬁcation improvement
was compared between the NICE guideline and both
ACC/AHA and ESC guidelines (18). All primary and
secondary endpoints are reported unadjusted. Data
are presented as mean  SD or mean differences with
95% CI. Statistical signiﬁcance was taken as 2-sided
p < 0.05.
RESULTS
DESCRIPTION OF STUDY COHORTS. The PROMISE
study population comprised 10,003 patients (age 61 
8 years, 53% female) without known CAD of whom
4,541 had interpretable CCTA results available.
The SCOT-HEART population included 3,770 patients
overall (376 patients excluded with known CAD)
(57  10 years, 46% female) of whom 1,619 had CCTA
results available. The number of patients identiﬁed as
low risk by the ACC/AHA, ESC, and NICE guidelines,
respectively, were 250 (2.5%), 251 (2.5%), and 1,002
(10.0%) within PROMISE, and 528 (14.0%), 748
(19.8%), and 1,447 (38.4%) within SCOT-HEART
(Table 1). Within both the SCOT-HEART and PROM-
ISE trial populations, there was substantial overlap
in individual patients identiﬁed as low risk by ACC/
AHA and ESC with 486 (SCOT-HEART) and 250
(PROMISE) patients classiﬁed as low risk by
both guidelines and only 42 (SCOT-HEART) and 1
(PROMISE) patients deemed low risk by ACC/AHA
were considered intermediate-high risk by ESC.
In contrast, there were 1,001 (SCOT-HEART) and
763 (PROMISE) patients deﬁned as low risk by NICE
who were classiﬁed as intermediate-high risk by
either ACC/AHA or ESC (Figure 1).
PREVALENCE OF CAD BY DIAGNOSTIC GROUPS.
Overall, obstructive CAD was identiﬁed in 537
patients (11.8%) in PROMISE and 359 (22.2%) in
TABLE 1 Baseline Characteristics by Guideline Risk Levels
ACC/AHA (2012) ESC (2013) NICE (2016)
Complete Trial CohortLow Risk High Risk Low Risk High Risk Low Risk High Risk
PROMISE
Patients 250 9,753 251 9,752 1,002 9,001 10,003
Age, yrs 55.0 (52.5–57.7) 60.3 (54.6–66.2) 55.0 (52.4–57.7) 60.3 (54.6–66.2) 60.3 (54.3–66.5) 59.9 (54.5–65.9) 60.0 (54.4–65.9)
Female 250 (100.0) 5,020 (51.5) 251 (100.0) 5,019 (51.5) 564 (56.3) 4,706 (52.3) 5,270 (52.7)
BMI, kg/m2 30.5 (25.8–35.0) 29.7 (26.4–33.9) 30.4 (25.8–35.0) 29.7 (26.4–33.9) 29.3 (26.0–33.5) 29.7 (26.4–34.0) 29.7 (26.3–33.9)
Hypertension 152 (60.8) 6,349 (65.1) 153 (61.0) 6,348 (65.1) 611 (61.0) 5,890 (65.4) 6,501 (65.0)
Hypercholesterolemia 156 (62.4) 6,611 (67.8) 157 (62.5) 6,610 (67.8) 654 (65.3) 6,113 (67.9) 6,767 (67.7)
Diabetes mellitus 39 (15.6) 2,105 (21.6) 39 (15.5) 2,105 (21.6) 179 (17.9) 1,965 (21.8) 2,144 (21.4)
Smoking history, current/ex 119 (47.6) 4,985 (51.1) 119 (47.4) 4,985 (51.1) 491 (49.0) 4,613 (51.3) 5,104 (51.0)
PAD or cerebrovascular disease 7 (2.8) 545 (5.6) 7 (2.8) 545 (5.6) 46 (4.6) 506 (5.6) 552 (5.5)
Family history 83 (33.3) 3,119 (32.1) 83 (33.2) 3,119 (32.1) 296 (29.6) 2,906 (32.4) 3,202 (32.1)
Anginal symptoms
Nonanginal 250 (100) 814 (8.3) 250 (99.6) 814 (8.3) 1,002 (100) 62 (0.7) 1,064 (10.6)
Atypical angina 0 (0) 7,773 (79.7) 1 (0.4) 7,772 (79.7) 0 (0) 7,773 (86.4) 7,773 (77.7)
Typical angina 0 (0) 1,116 (12.0) 0 (0) 1,166 (12.0) 0 (0) 1,166 (13.0) 1,166 (11.7)
Framingham 10-year CVD risk 8.7 (5.9–12.9) 17.4 (10.8–28.9) 8.7 (5.8–12.9) 17.4 (10.8–28.9) 15.6 (9.8–26.0) 17.3 (10.6–28.9) 17.1 (10.6–28.6)
SCOT-HEART
Patients 528 3,242 748 3,022 1,447 2,323 3,770
Age, yrs 50.0 (42.0–54.0) 59.0 (51.0–65.0) 51.0 (46.0–58.0) 59.0 (51.0–66.0) 54.0 (47.0–61.0) 59.0 (52.0–66.0) 57.0 (50.0–64.0)
Female 465 (88.1) 1,256 (38.7) 727 (97.2) 994 (32.9) 669 (46.2) 1,052 (45.3) 1,721 (45.6)
BMI, kg/m2 29.2 (25.0–34.5) 28.7 (25.7–32.5) 29.1 (25.0–34.6) 28.7 (25.7–32.4) 28.4 (25.1–32.7) 29.0 (25.9–32.9) 28.8 (25.6–32.8)
Hypertension 112 (21.5) 1,099 (34.2) 179 (24.2) 1,032 (34.4) 362 (25.3) 849 (36.8) 1,211 (32.4)
Hypercholesterolemia 176 (33.3) 1,902 (58.7) 284 (38.0) 1,794 (59.4) 580 (40.1) 1,498 (64.5) 2,078 (55.1)
Diabetes mellitus 38 (7.2) 332 (10.2) 58 (7.8) 312 (10.3) 115 (7.9) 255 (11.0) 370 (9.8)
Smoking history, current/ex 270 (51.1) 1,684 (52.0) 384 (51.3) 1,570 (52.0) 736 (50.9) 1,218 (52.5) 1,954 (51.9)
PAD or cerebrovascular disease 14 (2.7) 150 (4.7) 22 (3.0) 142 (4.7) 52 (3.6) 112 (4.8) 164 (4.4)
Family history 251 (47.8) 1,307 (40.7) 353 (47.6) 1,205 (40.3) 580 (40.6) 978 (42.4) 1,558 (41.7)
Anginal symptoms
Nonanginal 528 (100.0) 1,088 (33.6) 642 (85.8) 974 (32.2) 1,447 (100.0) 169 (7.3) 1,616 (42.9)
Atypical angina 0 (0.0) 893 (27.5) 106 (14.2) 787 (26.0) 0 (0.0) 893 (38.4) 893 (23.7)
Typical angina 0 (0.0) 1261 (38.9) 0 (0.0) 1261 (41.7) 0 (0.0) 1,261 (54.3) 1,261 (33.4)
Framingham 10-yr CVD risk 6.3 (3.6–9.3) 16.2 (10.0–25.2) 7.4 (4.2–11.2) 16.8 (10.3–25.9) 11.2 (6.6–18.2) 16.7 (9.6–27.0) 14.3 (8.4–23.5)
Values are n, median (interquartile range), n (%), mean  SD.
ACC/AHA¼ American College of Cardiology/American Heart Association; BMI ¼ body mass index; CVD ¼ cerebrovascular disease; ESC¼ European Society of Cardiology; NICE¼ National Institute of Health
and Care Excellence; PAD ¼ peripheral arterial disease; PROMISE ¼ Prospective Multicenter Imaging Study for Evaluation of Chest Pain; SCOT-HEART ¼ Scottish Computed Tomography of the Heart.
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1304SCOT-HEART. The prevalence of obstructive CAD
was <10% in the low-risk groups as determined by
all 3 guidelines within both study cohorts (Table 2),
and across both trials, the number of patients with
prognostically signiﬁcant CAD in the low- versus
intermediate-high–risk groups, respectively, was
1.3% versus 4.6% (ACC/AHA), 1.5% versus 4.7%
(ESC), and 2.4% versus 4.9% (NICE). For all com-
parisons, the OR for CAD was signiﬁcantly lower in
the low-risk than in intermediate-high–risk groups
(p < 0.05 for all) (Table 3). Compared with the ACC/
AHA and ESC deﬁnitions, respectively, applying the
NICE criteria resulted in a 12.6% and 10.6% net in-
crease in the proportion of patients without
obstructive CAD appropriately identiﬁed as low risk.There was a smaller net increase in the number of
patients with CAD inappropriately classiﬁed as low
risk (9.3% [ACC/AHA] and 8.6% [ESC]) (Online Ta-
ble 2). In comparison with both the ACC/AHA and
ESC classiﬁcations, the determination of low risk
according to the NICE guideline was associated with
greater diagnostic speciﬁcity (p < 0.001 for both) at
the expense of a decrease in sensitivity (p < 0.001
for both).
REVASCULARIZATION BY DIAGNOSTIC GROUPS.
During the ﬁrst 90 days following randomization,
469 patients (4.7%) in PROMISE and 251 (6.7%) in
SCOT-HEART underwent coronary revascularization
procedures. Across both trials, the frequencies of
revascularization within the low- versus
FIGURE 1 Diagnostic Group Classiﬁcation According to the ACC/AHA, ESC, and NICE
Guidelines
40%
30%
20%
10%
Low risk
(2.5%)
Low risk
(2.5%)
Low risk
(10.0%)
0%
ACC/AHA ESC NICE
ACCGuideline ESC NICE
PROMISE
Relative Size of Guideline-Determined Low-Risk Diagnostic GroupsA
B
Low risk
(14.0%)
Low risk
(19.8%)
Low risk
(38.4%)
ACC/AHA ESC NICE
SCOT-HEART
Low Risk Intermediate-High Risk
The American College of Cardiology/American Heart Association (ACC/AHA), European
Society of Cardiology (ESC), and National Institute of Health and Care Excellence (NICE)
guidelines are pink, green, and blue, respectively. (A) Proportion of study population
classiﬁed as low risk. (B) Overlap of diagnostic groups. Within this Euler diagram, the
area of each shaded circle represents the proportion of patients classiﬁed into the low-
and high-risk groups in the left- and right-hand panels, respectively. The combined area
of circles of the same color represents the entire analysis population and is the same for
all 3 colors corresponding to all 3 guidelines. Overlapping areas correspond to individual
patients who fulﬁll the criteria for low or high risk according to more than 1 guideline.
PROMISE ¼ Prospective Multicenter Imaging Study for Evaluation of Chest Pain; SCOT-
HEART ¼ Scottish Computed Tomography of the Heart.
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1305intermediate-high–risk groups were as follow: ACC/
AHA, 5 (0.7%) versus 717 (5.5%) (OR: 8.6; 95% CI: 3.6
to 20.8); ESC, 7 (0.7%) versus 715 (5.6%) (OR: 8.0; 95%
CI: 3.8 to 16.9); and NICE, 30 (2.0%) versus 692 (6.9%)
(OR: 3.5; 95% CI: 2.4 to 5.1) (p < 0.01 for all compar-
isons) (Table 4). In both trial cohorts, identiﬁcation
as low risk was associated with a negative predictive
value for coronary revascularization of >0.97 for
each of the 3 guidelines that was the same irre-
spective of guideline adopted (p > 0.05 for all).
In contrast, the positive predictive value for coronary
revascularization of the NICE classiﬁcation was
greater than either of the other guidelines (p < 0.001
for all).
CARDIOVASCULAR DEATH OR NONFATAL MYOCARDIAL
INFARCTION BY DIAGNOSTIC GROUPS. During follow-
up, 157 patients (1.6%) in PROMISE and 73 (1.9%) in
SCOT-HEART experienced a nonfatal myocardial
infarction or died from a cardiovascular cause. The
incidence rates per 100 patient-years within PROMISE
for the low- versus intermediate-high–risk groups
were as follow: ACC/AHA, 0.39 versus 0.78 (HR: 2.0;
95% CI: 0.5 to 8.1; p ¼ 0.330); ESC, 0.39 versus 0.78
(HR: 2.0; 95% CI: 0.5 to 8.1; p ¼ 0.326); and NICE, 0.43
versus 0.81 (HR: 1.84; 95% CI: 0.9 to 3.6; p ¼ 0.076).
The incidence rates within SCOT-HEART for the low-
versus intermediate-high–risk groups were as follow:
ACC/AHA, 0.12 versus 0.67 (HR: 5.8; 95% CI: 1.4 to
23.8; p ¼ 0.014); ESC, 0.16 versus 0.70 (HR: 4.3; 95%
CI: 1.6 to 11.8; p ¼ 0.005); and NICE, 0.36 versus 0.73
(HR: 2.1; 95% CI: 1.2 to 3.6; p ¼ 0.009) (Table 5). On
analysis of both trial cohorts in combination,
although the negative predictive value for cardio-
vascular death or nonfatal myocardial infarction was
lower when applying the NICE classiﬁcation than
either the ACC/AHA (p ¼ 0.034) or ESC (p ¼ 0.047)
strategies, it remained >0.98 for each of the 3
guidelines.
DISCUSSION
Identifying which patients require additional testing
is a central component of the care of stable symp-
tomatic patients with suspected CAD. Because the
approach to doing so and resulting recommenda-
tions differ across the 3 major international guide-
lines, which together represent the current standard
of care across Europe and North America, we
compared their application within 2 large,
geographically distinct, randomized trial pop-
ulations. Despite the substantial demographic and
clinical practice differences between these cohorts,
we have demonstrated proportionally consistentﬁndings. In both trials, the use of a symptom-
focused strategy endorsed by NICE, in contrast
with a Bayesian–risk based approach endorsed by
ACC/AHA and ESC, resulted in a 3- to 4-fold increase
in the number of patients for whom no further
investigation for the presence of CAD is recom-
mended. This is reassuring given concerns raised
recently that the updated NICE guidance would lead
TABLE 2 Patient Outcomes by Guideline Risk Levels
ACC (2012) ESC (2013) NICE (2016)
Low Risk High Risk Low Risk High Risk Low Risk High Risk
PROMISE
Patients 250 9,753 251 9,752 1,002 9,001
CAD on CCTA 108 4,433 108 4,433 456 4,085
Normal 55 (50.9) 1,463 (33.0) 55 (50.9) 1,463 (33.0) 155 (34.0) 1,363 (33.4)
Mild CAD 50 (46.3) 2,436 (55.0) 50 (46.3) 2,436 (55.0) 262 (57.5) 2,224 (54.4)
Obstructive CAD 3 (2.8) 534 (12.0) 3 (2.8) 534 (12.0) 39 (8.6) 498 (12.2)
Prognostically signiﬁcant CAD* 0 (0) 144 (3.2) 0 (0) 144 (3.2) 11 (2.4) 133 (3.3)
Subsequent coronary revascularization—90 days 3 (1.2) 468 (4.8) 3 (1.2) 468 (4.8) 23 (2.3) 448 (5.0)
PCI 3 (1.2) 361 (3.7) 3 (1.2) 361 (3.7) 22 (2.2) 342 (3.8)
CABG 0 (0.0) 107 (1.1) 0 (0.0) 107 (1.1) 1 (0.1) 106 (1.2)
CVD death or nonfatal MI—1 yr 2 (0.8) 155 (1.6) 2 (0.8) 155 (1.6) 9 (0.9) 148 (1.6)
SCOT-HEART
Patients 528 3,242 748 3,022 1,447 2,323
CAD on CCTA 193 1,426 305 1,314 591 1,028
Normal 138 (71.5) 498 (34.9) 198 (64.9) 438 (33.3) 296 (50.1) 340 (33.1)
Mild CAD 46 (23.8) 578 (40.5) 92 (30.2) 532 (40.5) 239 (40.4) 385 (37.5)
Obstructive CAD 9 (4.7) 350 (24.5) 15 (4.9) 344 (26.2) 56 (9.5) 303 (29.5)
Prognostically signiﬁcant CAD* 4 (2.1) 127 (8.9) 6 (2.0) 125 (9.5) 12 (2.0) 119 (11.6)
Subsequent coronary revascularization—90 days 2 (0.4) 249 (7.7) 4 (0.5) 247 (8.2) 7 (0.5) 244 (10.5)
PCI 2 (0.4) 217 (6.7) 4 (0.5) 215 (7.1) 7 (0.5) 212 (9.1)
CABG 0 (0.0) 33 (1.0) 0 (0.0) 33 (1.1) 0 (0.0) 33 (1.4)
CVD death or nonfatal MI—3 yrs 2 (0.4) 71 (2.2) 4 (0.5) 69 (2.3) 17 (1.2) 56 (2.4)
Values are n or n (%). *Prognostically signiﬁcant CAD was deﬁned as 3-vessel disease, 2-vessel disease including the proximal left anterior descending artery, or obstructive
disease involving the left main stem.
CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; CCTA ¼ coronary computed tomography angiography; MI ¼ myocardial infarction; PCI ¼ percutaneous
coronary intervention; other abbreviations as in Table 1.
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1306to an increase in indiscriminate diagnostic testing
(19), as well as strategies being considered to defer
testing in those patients with very low risk (20,21).
Furthermore, the group designated by NICE for no
testing (nonanginal symptoms) demonstrated <10%
prevalence of coronary obstruction across both trial
cohorts, below the threshold adjudged to reﬂect low
risk in both the ACC/AHA and ESC guidelines. These
ﬁndings strongly support the use of characterization
of patient symptoms as central in the assessment of
suspected stable angina.
Recently, in part prompted by rapid advances in
coronary CT, extensive research has been undertaken
to clarify the relative merits of noninvasive imaging
modalities in the assessment of suspected stable
angina. Indeed, both PROMISE and SCOT-HEART
were designed to test the hypothesis that CCTA
might improve clinical outcomes compared with
established, usual care approaches. In this context,
CCTA increases diagnostic certainty and may reduce
cardiovascular events (8,9,22).
In practice however, it is well appreciated that
many patients undergoing assessment for possiblestable angina are at low risk of both underlying CAD
and future ischemic events, at least in the short to
medium term. In the primary care setting, <10% of
such patients are ultimately identiﬁed as having a
coronary cause for their symptoms (23). Recognizing
this, substantial work has been done to update,
reﬁne, and extend risk models for estimating the PTP
CAD, albeit often in highly selected populations
referred for invasive angiography (24–28). In stark
contrast, there is a dearth of trial evidence to support
the clinical efﬁcacy of the risk thresholds recom-
mended within the guidelines and it seems plausible
that although symptom characterization has recog-
nized value in all these guidelines, its importance
continues to be undervalued (29). Temporal trends
described in patients undergoing nuclear testing
offer valuable insight in this regard. In a report of
nearly 40,000 patients covering the period 1991
to 2009, the proportion of patients referred for
myocardial perfusion imaging with inducible
ischemia fell from 30% to 5% (30). This occurred
despite increasing prevalence of cardiovascular
risk factors and a corresponding increase in the
TABLE 3 Association Between Guideline Risk Level and Obstructive CAD by Guideline
Guideline (Year)
Obstructive CAD
(Events/Sample Size) Unadjusted* Performance Measures
High Risk
n/n (%)
Low Risk
n/n (%)
OR
(95% CI) p Value
C Statistic
(95% CI)
Sensitivity
(95% CI)
Speciﬁcity
(95% CI)
PPV
(95% CI)
NPV
(95% CI)
PROMISE
ACC/AHA (2012) 534/4,433
(12.05)
3/108
(2.78)
4.79
(1.52–15.16)
0.008 0.510
(0.506–0.514)
0.994
(0.984–0.999)
0.026
(0.022–0.032)
0.120
(0.111–0.130)
0.972
(0.921–0.994)
ESC (2013) 534/4,433
(12.05)
3/108
(2.78)
4.79
(1.52–15.16)
0.008 0.510
(0.506–0.514)
0.994
(0.984–0.999)
0.026
(0.022–0.032)
0.120
(0.111–0.130)
0.972
(0.921–0.994)
NICE (2016) 498/4,085
(12.19)
39/456
(8.55)
1.48
(1.06–2.09)
0.023 0.516
(0.504–0.528)
0.927
(0.902–0.948)
0.104
(0.095–0.114)
0.122
(0.112–0.132)
0.914
(0.885–0.939)
SCOT-HEART
ACC/AHA (2012) 350/1,426
(24.5)
9/193
(4.7)
6.65
(3.37–13.13)
<0.001 0.560
(0.548–0.573)
0.975
(0.966–0.981)
0.146
(0.130–0.164)
0.245
(0.225–0.267)
0.953
(0.942–0.963)
ESC (2013) 344/1,314
(26.2)
15/305
(4.9)
6.86
(4.02–11.69)
<0.001 0.594
(0.579–0.610)
0.958
(0.947–0.967)
0.230
(0.210–0.251)
0.262
(0.241–0.284)
0.951
(0.939–0.960)
NICE (2016) 303/1,028
(29.5)
56/591
(9.5)
3.99
(2.94–5.42)
<0.001 0.634
(0.611–0.658)
0.844
(0.826–0.861)
0.425
(0.401–0.449)
0.295
(0.273–0.317)
0.905
(0.890–0.919)
*Unadjusted model contains referral to guideline risk level (intermediate/high vs. low).
CI ¼ conﬁdence interval; NPV ¼ negative predictive value; OR ¼ odds ratio; PPV ¼ positive predictive value; other abbreviations as in Table 1.
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1307calculated PTP of CAD within this cohort. Similar
declining rates of positive ischemia tests have been
described elsewhere (31,32). Interestingly, over the
same time period, the proportion of these patients
with typical angina symptoms fell from 13% to 2%,
whereas those reporting only dyspnea in the absence
of chest discomfort, increased from 5% to 11% (30).
This association places further emphasis on the need
for accurate symptom characterization to lie at the
center of decision making and is entirely consistent
with our analysis, wherein we identiﬁed a substantialTABLE 4 Association Between Guideline Risk Level and Revasculariz
Guideline (Year)
Frequency of
Revascularization
(Events/Sample Size) Unadjusted*
High Risk
n/n (%)
Low Risk
n/n (%)
OR
(95% CI) p Value
PROMISE
ACC/AHA (2012) 466/9,753
(4.78)
3/250
(1.20)
4.13
(1.32–12.95)
0.015
ESC (2013) 466/9,752
(4.78)
3/251
(1.20)
4.15
(1.32–13.00)
0.015
NICE (2016) 446/9,001
(4.96)
23/1,002
(2.30)
2.22
(1.45–3.39)
<0.001
SCOT-HEART
ACC/AHA (2012) 249/3,242
(7.7)
2/528
(0.4)
21.88
(5.43–88.25)
<0.001
ESC (2013) 247/3,022
(8.2)
4/748
(0.5)
16.56
(6.15–44.59)
<0.001
NICE (2016) 244/2,323
(4.8)
7/1,447
(0.5)
24.14
(11.36–51.34)
<0.001
*Unadjusted model contains referral to guideline risk level (intermediate/high vs. low).
Abbreviations as in Tables 1 and 3.increase in diagnostic speciﬁcity when applying
the symptom-focused NICE guideline compared with
either of the alternative approaches.
Although our ﬁndings were proportionally similar
across both study cohorts, important differences in
trial design likely explain the differences in overall
percentages of patients within each of the diagnostic
groups. The trial inclusion criteria in PROMISE
stipulated that physicians had predetermined a
requirement for noninvasive testing, whereas
SCOT-HEART enrolled all patients referred to theation Within 90 Days of Randomization
Performance Measures
C Statistic
(95% CI)
Sensitivity
(95% CI)
Speciﬁcity
(95% CI)
PPV
(95% CI)
NPV
(95% CI)
0.510
(0.506–0.514)
0.994
(0.981–0.999)
0.026
(0.023–0.029)
0.048
(0.044–0.052)
0.988
(0.965–0.998)
0.510
(0.506–0.514)
0.994
(0.981–0.999)
0.026
(0.023–0.029)
0.048
(0.044–0.052)
0.988
(0.966–0.998)
0.527
(0.517–0.537)
0.951
(0.927–0.969)
0.103
(0.097–0.109)
0.050
(0.045–0.054)
0.977
(0.966–0.985)
0.571
(0.563–0.579)
0.992
(0.989–0.994)
0.149
(0.138–0.161)
0.077
(0.069–0.086)
0.996
(0.994–0.998)
0.598
(0.587–0.608)
0.984
(0.980–0.988)
0.211
(0.199–0.225)
0.082
(0.073–0.091)
0.995
(0.992–0.997)
0.691
(0.678–0.704)
0.972
(0.966–0.977)
0.409
(0.394–0.425)
0.105
(0.096–0.115)
0.995
(0.992–0.997)
TABLE 5 Association Between Guideline Risk Level and CVD Death/MI
Guideline (Year)
Incidence Rate per
100 Patient-Years Unadjusted* Performance Measures
High Risk
(95% CI)
Low Risk
(95% CI)
HR
(95% CI) p Value
C Statistic
(95% CI)
Sensitivity
(95% CI)
Speciﬁcity
(95% CI)
PPV
(95% CI)
NPV
(95% CI)
PROMISE
ACC/AHA (2012) 0.78
(0.67–0.92)
0.39
(0.10–1.55)
2.00
(0.50–8.07)
0.330 0.508
(0.499–0.516)
0.987
(0.955–0.999)
0.025
(0.022–0.029)
0.016
(0.014–0.019)
0.992
(0.971–0.999)
ESC (2013) 0.78
(0.67–0.92)
0.39
(0.10–1.54)
2.01
(0.50–8.12)
0.326 0.508
(0.499–0.516)
0.987
(0.955–0.999)
0.025
(0.022–0.028)
0.016
(0.014–0.019)
0.992
(0.972–0.999)
NICE (2016) 0.81
(0.69–0.95)
0.43
(0.23–0.83)
1.84
(0.94–3.61)
0.076 0.524
(0.505–0.543)
0.943
(0.894–0.974)
0.101
(0.095–0.107)
0.016
(0.014–0.019)
0.991
(0.983–0.996)
SCOT-HEART
ACC/AHA (2012) 0.67
(0.52–0.84)
0.12
(0.01–0.42)
5.85
(1.44–23.85)
0.014 0.557
(0.538–0.577)
0.973
(0.967–0.977)
0.142
(0.131–0.154)
0.022
(0.018–0.027)
0.996
(0.994–0.998)
ESC (2013) 0.70
(0.54–0.88)
0.16
(0.04–0.42)
4.31
(1.57–11.80)
0.005 0.573
(0.546–0.600)
0.945
(0.937–0.952)
0.201
(0.189–0.214)
0.023
(0.019–0.028)
0.995
(0.992–0.997)
NICE (2016) 0.73
(0.55–0.95)
0.36
(0.21–0.58)
2.07
(1.20–3.56)
0.009 0.577
(0.528–0.626)
0.767
(0.753–0.780)
0.387
(0.371–0.402)
0.024
(0.020–0.030)
0.988
(0.984–0.991)
*Unadjusted model contains referral to guideline risk level (intermediate/high vs. low).
HR ¼ hazard ratio; other abbreviations as in Tables 1 and 2.
Adamson et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 1 1 , N O . 9 , 2 0 1 8
Assessment of Stable Angina: Comparison of Guidelines S E P T E M B E R 2 0 1 8 : 1 3 0 1 – 1 0
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This may account for why individuals presenting
with chest pain classiﬁed as nonanginal comprised
merely 11% within PROMISE compared with 41%
in SCOT-HEART. In contrast, only 72% of patients
within PROMISE described chest pain as the primary
symptom compared with the entire SCOT-HEART
cohort (10), perhaps explaining the 2-fold greater
prevalence of obstructive CAD in the latter, despite
comprising a population at apparently lower cardio-
vascular risk, as determined by the Framingham
score.
Whereas a Bayesian probabilistic approach to pa-
tient selection has many theoretical advantages, our
results point toward a key limitation in this strategy.
Namely, that despite revisions, risk models continue
to both over- and underestimate disease prevalence
(9,33–38) when applied in settings external to the
derivation cohort. Given it is the presence of symp-
toms that identiﬁes patients with suspected angina, it
would appear to follow that it is the nature of these
symptoms that should inform diagnostic decisions.
This perhaps explains why removing cardiovascular
risk factors—namely age and sex—that are common to
both the ACC/AHA and ESC guidelines, results in the
NICE guideline’s improved diagnostic discrimination
(39). Crucially, this approach appears safe, as the
prevalence of CAD remained below 10% among pa-
tients with nonanginal symptoms in both trial
cohorts.
STUDY STRENGTHS AND LIMITATIONS. Our study
has several notable strengths. Both the PROMISE and
SCOT-HEART trials were pragmatic in design andenrolled patients that accurately reﬂect the real-
world suspected angina population. Despite its post
hoc nature, this analysis combines the 2 largest
prospective trials of CCTA for stable angina to date,
and the enrolled sample size and clinical and
geographic diversity of these study cohorts provides
robust evidence that our ﬁndings are applicable
across international boundaries and in a variety of
clinical settings. In both cases, patient characteristics
regarding symptoms, cardiovascular risk factors,
noninvasive test results and clinical endpoints were
collected in a systematic manner with minimal loss to
follow-up. Any minor differences between trials in
data collection are minimized because all analyses
comparing guidelines were conducted within each
trial rather than in combined data. We chose to
combine both intermediate- and high-risk individuals
into a single intermediate-high–risk category, a
necessary deviation from ACC/AHA and ESC guideline
recommendations, to allow comparison of those
who do versus do not need testing and to allow direct
comparison with the 2 diagnostic groups created by
the NICE guideline. Although CCTA has limitations in
the diagnosis of CAD, these principally relate to sub-
optimal speciﬁcity and a tendency to overestimate
stenosis severity. In contrast, the very high diagnostic
sensitivity offered by CCTA provides necessary reas-
surance regarding the ability of all strategies to
exclude signiﬁcant CAD. Importantly, the disease
prevalence identiﬁed is unlikely to be an underesti-
mate, and in fact the rates of CAD may be lower than
we have reported in both the low- and high-risk
diagnostic groups.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In the assess-
ment of suspected stable angina, noninvasive diagnostic imaging
is recommended for intermediate-risk patients.
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: Compared with traditional risk-based approaches,
greater emphasis on symptomatology following careful clinical
history taking can safely identify a greater number of patients at
low risk of CAD and may reduce the requirement for additional
investigations.
TRANSLATIONAL OUTLOOK 1: Updated clinical guidelines
should place greater emphasis on the importance of patient
symptoms in identifying appropriate individuals for diagnostic
testing.
TRANSLATIONAL OUTLOOK 2: The clinical outcomes arising
from international guidelines should be robustly evaluated to
ensure they achieve optimal safety and efﬁcacy.
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1309CONCLUSIONS
All 3 current guidelines identify low-risk groups
in both PROMISE and SCOT-HEART who have
lower prevalence of CAD, including prognostically
signiﬁcant CAD, as well as fewer revascularizations
and adverse events. Compared with traditional,
risk-based guidelines, a symptom-focused strategy
classiﬁes a greater proportion of chest pain patients
as low risk. Using this strategy has the potential
to substantially reduce the use of downstream
investigations in the diagnosis of suspected stable
angina. These results suggest that a symptom-
focused assessment may safely and efﬁciently iden-
tify low-risk patients deriving limited beneﬁt from
noninvasive testing.
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